Integrating clonal haematopoiesis into geriatric oncology: The ARCH between aging, cardiovascular disease and malignancy
- PMID: 32978103
- DOI: 10.1016/j.jgo.2020.09.006
Integrating clonal haematopoiesis into geriatric oncology: The ARCH between aging, cardiovascular disease and malignancy
Keywords: Age-related clonal haematopoiesis (ARCH); Cardiovascular risk; Clonal haematopoiesis of indeterminate potential (CHIP); Therapy-related neoplasia; Tumour microenvironment.
Conflict of interest statement
Declaration of Competing Interest N.R.N. has received honoraria and travel support by Janssen-Cilag, Medac, Novartis, and Jazz Pharmaceutical. C.F. received honoraria and travel grants from Roche, Celgene, Pfizer, Amgen, and Astra Zeneca. L.P·F reports grants from Gilead and Roche, and honoraria from AbbVie. F.L. has nothing to disclose.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
